Stifel raised the firm’s price target on Zimmer Biomet (ZBH) to $118 from $115 and keeps a Buy rating on the shares following orthopedic surgeon checks on the recent launches of Oxford Cementless and Osseofit. The feedback from doctors is encouraging and indicates broad adoption and growth ahead for Zimmer, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Target initiated, Nike upgraded: Wall Street’s top analyst calls
- Zimmer Biomet initiated with a Buy at Rothschild & Co Redburn
- Zimmer Biomet Holdings: Operational Improvements and Strategic Positioning Amid Cautious Growth Prospects
- Zimmer Biomet Holdings: Stable Performance with Limited Growth Prospects Justifies Hold Rating
- Zimmer Biomet Issues CHF 600 Million Debt Securities